We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Thrombolysis in Myocardial Infarction (TIMI)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000505
First Posted: October 28, 1999
Last Update Posted: March 16, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
  Purpose
In TIMI I, to assess the relative thrombolytic activity and side effects of intravenous recombinant tissue-type plasminogen activator (rt-PA) versus intravenous streptokinase in patients with acute myocardial infarction. In TIMI II, to assess whether intravenous rt-PA given in the early hours of acute myocardial infarction should be followed by percutaneous transluminal coronary angioplasty (PTCA).

Condition Intervention Phase
Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Infarction Myocardial Ischemia Drug: tissue plasminogen activator Procedure: angioplasty, transluminal, percutaneous coronary Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: April 1983
Study Completion Date: December 1990
  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Men and women under age 76. Patients had acute myocardial infarction.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000505


Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
OverallOfficial: Joseph Babb Bridgeport Hospital
OverallOfficial: Jeffery Borer Weill Medical College of Cornell University
OverallOfficial: Bernard Chaitman St. Louis University Medical Center
OverallOfficial: James Chesebro Mayo Foundation
OverallOfficial: Richard Davison Northwestern University
OverallOfficial: Harold Dodge University of Washington
OverallOfficial: Frederick Feit New York University School of Medicine
OverallOfficial: Charles Francis Yale University
OverallOfficial: Joel Gore University of Massachusetts, Worcester
OverallOfficial: Michael Herman New York Medical College
OverallOfficial: Morrison Hodges University of Minnesota - Clinical and Translational Science Institute
OverallOfficial: Harvey Kemp St. Luke's-Roosevelt Institute for Health Sciences
OverallOfficial: Genell Knatterud Maryland Medical Research Institute
OverallOfficial: Costas Lambrew Maine Medical Center
OverallOfficial: Philip Ludbrook Washington University School of Medicine
OverallOfficial: Kenneth Mann University of Vermont
OverallOfficial: John Markis Beth Israel Hospital
OverallOfficial: John Morrison North Shore University Hospital
OverallOfficial: Hiltrud Mueller Montefiore Medical Center
OverallOfficial: Eric Powers Columbia University
OverallOfficial: Robert Roberts Baylor College of Medicine
OverallOfficial: Williams Rogers University of Alabama at Birmingham
OverallOfficial: Allan Ross George Washington University
OverallOfficial: Thomas Ryan University Hospital Inc.
OverallOfficial: Marc Schweiger Baystate Medical Center
OverallOfficial: Gerald Timmis William Beaumont Hospitals
OverallOfficial: James Willerson University of Texas
OverallOfficial: David Williams Rhode Island Hospital
OverallOfficial: Barry Zaret Yale University
  More Information

Publications:
Bovill E: Dose Response Relationship of rt-PA Infusion to Induction of Systemic Fibrin(ogen)olysis in the Thrombolysis in Myocardial Infarction (TIMI) Trial. Blood, 70(Suppl 1) 367a, 1987.

ClinicalTrials.gov Identifier: NCT00000505     History of Changes
Other Study ID Numbers: 24
R01HL042311 ( U.S. NIH Grant/Contract )
First Submitted: October 27, 1999
First Posted: October 28, 1999
Last Update Posted: March 16, 2016
Last Verified: July 2000

Additional relevant MeSH terms:
Infarction
Cardiovascular Diseases
Heart Diseases
Myocardial Infarction
Ischemia
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Pathologic Processes
Necrosis
Vascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Plasminogen
Tissue Plasminogen Activator
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action